| 8:30 AM - 9:00 AM | Check-in and Breakfast |
| 9:00 AM - 10:00 AM | Session I: Welcome Remarks & Opening Keynote Chairperson: Kyle Flannigan, PhD, Boehringer Ingelheim
9:00 AM
Welcome Remarks
Cassie Chartier, PhD, The New York Academy of Sciences
Kyle Flannigan, PhD, Boehringer Ingelheim
Vincent Fiore, PhD, Boehringer Ingelheim
9:15 AM
Opening Keynote Presentation: Temporal Multiomics in Fibrosis Resolution
Michael Longaker, MD, Stanford University
|
| 10:00 AM - 10:30 AM | Networking Break |
| 10:30 AM - 12:10 PM | Session II: Biology of Fibrosis Chairperson: Vincent Fiore, PhD, Boehringer Ingelheim
10:30 AM
Molecular Pathways Involved in Liver Repair and Fibrosis
Scott Friedman, MD, The Icahn School of Medicine at Mount Sinai
10:55 AM
Regulation of Fibroblasts and Inflammation in Tissue Fibrosis and Post-Fibrotic Resolution
Valerie Horsley, PhD, Yale University
11:20 AM
Mechanisms of Fibrosis in IBD
Florian Rieder, MD, Cleveland Clinic
11:45 PM
Mechanobiology in Persistent and Resolving Organ Fibrosis
Daniel J. Tschumperlin, PhD, Mayo Clinic |
| 12:10 PM - 1:25 PM | Networking Lunch and Poster Session |
| 1:25 PM - 1:45 PM | Session III: Short Talks From Selected Abstracts Chairperson: Kyle Flannigan, PhD, Boehringer Ingelheim |
| 1:45 PM - 3:00 PM | Session IV: Multiomics Signatures Chairperson: Andres Hurtado-Lorenzo, PhD, Crohn's & Colitis Foundation
1:45 PM
Multiomics of Skin Pathology and Immune Regulation
Shruti Naik, PhD, The Icahn School of Medicine at Mount Sinai
2:10 PM
Multiomic Endotypes in Fibrostenotic Crohn’s Disease
Lee Denson, MD, Cincinnati Children’s Hospital and Medical Center
2:35 PM
Spatial Profiling of Human Liver Fibrosis
Neil Henderson, MD, University of Edinburgh |
| 3:00 PM - 3:30 PM | Networking Break |
| 3:30 PM - 5:30 PM | Session V: Therapeutic Approaches to Fibrosis Chairperson: Scott MacDonnell, PhD, Regeneron
3:30 PM
Mechanism of Action of Nerandomilast in Pulmonary Fibrosis
Carine Boustany, PhD, Boehringer Ingelheim
3:55 PM
From Mouse to Human: Translational Modeling of Intestinal Fibrosis in IBD
Scott MacDonnell, PhD, Regeneron
4:20 PM
Gut Restricted PED4 Inhibitor for the Treatment of Fibrostenosing Crohn’s Disease
Mitchell Jones, MD, PhD, Palisade Bio
4:45 PM
Closing Keynote Presentation: Fibrosis — From Mechanisms to Medicines
Thomas A Wynn, PhD, Pfizer |
| 5:30 PM - 5:35 PM | Closing Remarks Cassie Chartier, PhD, The New York Academy of Sciences |